DexCom reported Q3 2024 revenue of $994.2 million, up 2% year-over-year. U.S. revenue declined 2% to $701.9 million, while international revenue grew 12% to $292.3 million. GAAP operating income was $152.0 million or 15.3% of revenue, down from 21.1% in Q3 2023.The company launched Stelo, an over-the-counter glucose biosensor for adults with prediabetes and type 2 diabetes not on insulin therapy. DexCom also expanded internationally, launching G7 in Australia and ONE+ in France. A $750 million share repurchase program was executed in Q3.DexCom reaffirmed its 2024 guidance, projecting revenue of $4.00-4.05 billion (11-13% organic growth) and a non-GAAP operating margin of approximately 20%. The company also announced that Chief Commercial Officer Teri Lawver will retire at year-end, with CEO Kevin Sayer assuming leadership of the commercial organization during the search for a successor.

DexCom reported Q3 2024 revenue of $994.2 million, up 2% year-over-year. U.S. revenue declined 2% to $701.9 million, while international revenue grew 12% to $292.3 million. GAAP operating income was $152.0 million or 15.3% of revenue, down from 21.1% in Q3 2023.The company launched Stelo, an over-the-counter glucose biosensor for adults with prediabetes and type 2 diabetes not on insulin therapy. DexCom also expanded internationally, launching G7 in Australia and ONE+ in France. A $750 million share repurchase program was executed in Q3.DexCom reaffirmed its 2024 guidance, projecting revenue of $4.00-4.05 billion (11-13% organic growth) and a non-GAAP operating margin of approximately 20%. The company also announced that Chief Commercial Officer Teri Lawver will retire at year-end, with CEO Kevin Sayer assuming leadership of the commercial organization during the search for a successor.